At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IMVT Immunovant, Inc.
Pre-Market Trading 05-21 08:21:02 EDT
30.87
+0.17
+0.55%
High30.95
Low30.37
Vol585.13K
Open30.69
D1 Closing30.70
Amplitude1.89%
Mkt Cap4.49B
Tradable Cap1.98B
Total Shares145.29M
T/O17.99M
T/O Rate0.91%
Tradable Shares64.26M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
North American Morning Briefing: Stocks Drift as Metals Hover Around Records
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.